Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial. Issue 1 (December 2016)
- Record Type:
- Journal Article
- Title:
- Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial. Issue 1 (December 2016)
- Main Title:
- Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial
- Authors:
- Takekita, Yoshiteru
Koshikawa, Yosuke
Fabbri, Chiara
Sakai, Shiho
Sunada, Naotaka
Onohara, Ai
Nishida, Keiichiro
Yoshimura, Masafumi
Kato, Masaki
Serretti, Alessandro
Kinoshita, Toshihiko - Abstract:
- Abstract Background Recently, long-acting injection (LAI) of second-generation antipsychotics has become a valuable strategy for the treatment of schizophrenia. However, few studies have compared the effects of different LAI antipsychotics on cognitive functions so far. The present study aimed to compare the influence of risperidone LAIs (RLAI) and paliperidone palmitate LAIs (PP) on cognitive function in outpatients with schizophrenia. Methods In this 6-month, open-label, randomized, and controlled study, 30 patients with schizophrenia who were treated with RLAIs were randomly allocated to the RLAI-continued group or the PP group. At baseline and 6 months, the patients were evaluated using the Brief Assessment of Cognition in Schizophrenia (BACS) that was the primary outcome of the study. The Subjective Well-being under Neuroleptic drug treatment-Short form (SWNS), the Positive and Negative Syndrome Scale (PANSS), and the Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) scores were secondary outcome variables and they were tested at the same time points. Results The two groups did not differ in terms of PANSS, DIEPSS, or SWNS total score changes. However, the BACS score for the attention and processing speed item showed higher improvement in the PP group than the RLAI group (p = 0.039). Conclusions The results of this preliminary study suggest that PPs may improve attention and processing speed more than RLAIs. Anyway, a replication in a larger and double-blind study isAbstract Background Recently, long-acting injection (LAI) of second-generation antipsychotics has become a valuable strategy for the treatment of schizophrenia. However, few studies have compared the effects of different LAI antipsychotics on cognitive functions so far. The present study aimed to compare the influence of risperidone LAIs (RLAI) and paliperidone palmitate LAIs (PP) on cognitive function in outpatients with schizophrenia. Methods In this 6-month, open-label, randomized, and controlled study, 30 patients with schizophrenia who were treated with RLAIs were randomly allocated to the RLAI-continued group or the PP group. At baseline and 6 months, the patients were evaluated using the Brief Assessment of Cognition in Schizophrenia (BACS) that was the primary outcome of the study. The Subjective Well-being under Neuroleptic drug treatment-Short form (SWNS), the Positive and Negative Syndrome Scale (PANSS), and the Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) scores were secondary outcome variables and they were tested at the same time points. Results The two groups did not differ in terms of PANSS, DIEPSS, or SWNS total score changes. However, the BACS score for the attention and processing speed item showed higher improvement in the PP group than the RLAI group (p = 0.039). Conclusions The results of this preliminary study suggest that PPs may improve attention and processing speed more than RLAIs. Anyway, a replication in a larger and double-blind study is needed. Trial registration UMIN000014470 . Registered 10 July 2014 … (more)
- Is Part Of:
- BMC psychiatry. Volume 16:Issue 1(2016)
- Journal:
- BMC psychiatry
- Issue:
- Volume 16:Issue 1(2016)
- Issue Display:
- Volume 16, Issue 1 (2016)
- Year:
- 2016
- Volume:
- 16
- Issue:
- 1
- Issue Sort Value:
- 2016-0016-0001-0000
- Page Start:
- 1
- Page End:
- 8
- Publication Date:
- 2016-12
- Subjects:
- Schizophrenia -- Risperidone long-acting injection -- Paliperidone palmitate -- Cognitive function -- Efficacy -- Subjective well-being
Psychiatry -- Periodicals
616.89005 - Journal URLs:
- http://www.biomedcentral.com/bmcpsychiatr/ ↗
http://www.pubmedcentral.nih.gov/tocrender.fcgi?journal=62 ↗
http://link.springer.com/ ↗ - DOI:
- 10.1186/s12888-016-0883-9 ↗
- Languages:
- English
- ISSNs:
- 1471-244X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 9902.xml